2021 Fiscal Year Final Research Report
The elucidation of the predictive of psychological changes by chemotherapy mediated the serotonin-kynurenine pathway
Project/Area Number |
19K07192
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 47060:Clinical pharmacy-related
|
Research Institution | Shujitsu University (2020-2021) Okayama University (2019) |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
浅沼 幹人 岡山大学, 医歯薬学総合研究科, 教授 (00273970)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 抗がん剤 / 不安 / AC療法 / 神経新生 / セロトニン / キヌレニン / セロトニン1A受容体作用薬 |
Outline of Final Research Achievements |
Serotonin (5-HT) are widely distributed throughout the brain and are involved in the regulation of mood disorders. We demonstrated that the combination of doxorubicin and cyclophosphamide induced anxiety-like behavior. We proposed that the anxiety-like behavior induced by the combination of doxorubicin and cyclophosphamide is mediated by 5-HT2A receptor hyperactivity. And, the combination of doxorubicin and cyclophosphamide induced anxiety-like behavior by 5-HT2A receptor hyperactivity via the phosphorylation of ERK1/2. Furthermore, selective serotonin reuptake inhibitors may attenuate the anxiolytic effects induced by the combination of doxorubicin and cyclophosphamide. Furthermore, a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist ameliorated chemotherapy-induced anxiety-like behavior in rats. Thus, 5-HT2A receptor antagonists or 5-HT1A receptor agonists might be useful for treating chemotherapy-induced anxiety disorders.
|
Free Research Field |
精神神経薬理学
|
Academic Significance and Societal Importance of the Research Achievements |
日本人の3人に1人はがんで亡くなる。また、がんと診断を受けた患者の多くは精神的な負担を強いられ、抗がん剤をはじめとした治療の拒否へともつながる。本研究では抗がん剤は不安症状といった精神的な負担を誘発することを明らかにした。その原因は中枢神経系の機能低下によるものであり、ストレスに弱い脳になることを明らかにした。また、治療薬も明らかにし、今後益々増加するがん患者の健全な精神機能の維持に貢献できた。
|